Volume 14, Issue 3 (11-2000)                   Med J Islam Repub Iran 2000 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BEHTASH N, MODARES M, GHAEM-MAGHAMI F, MOUSAVI A, SALEHI K. NEOADJUVANT CHEMOTHERAPY WITH VINCRISTINE AND CISPLATIN FOLLOWED BY RADICAL HYSTERECTOMY AND PELVIC LYMPH ADENECTOMY FOR FIGO STAGE IB BULKY CERVICAL CANCER. Med J Islam Repub Iran 2000; 14 (3) :241-243
URL: http://mjiri.iums.ac.ir/article-1-861-en.html
NEOADJUVANT CHEMOTHERAPY WITH VINCRISTINE AND CISPLATIN FOLLOWED BY RADICAL HYSTERECTOMY AND PELVIC LYMPH ADENECTOMY FOR FIGO STAGE IB BULKY CERVICAL CANCER
N BEHTASH , M MODARES , F GHAEM-MAGHAMI , A MOUSAVI , K SALEHI
From the Department of Gynecology-Oncology, Vali-E-Asr Hospital, Tehran University 0F Medical Sciences, Tehran, I.R. Iran.
Abstract:   (4566 Views)
Twenty patients with bulky (>4 cm size) FIGO stage IB cervical cancer were treated with cisplatin 50 mg/m2 and vincristine 1 mg/m2, administered intravenously at 10-day intervals for a total of 3 courses before radical hysterectomy. A complete clinical response was noted in 1 patient (5%) and partial response in 5 (25%). Fourteen patients (70%) had stable disease. There was no grade 3 toxicity noted. Of the 20 patients who received chemotherapy (ChT), 3 patients had parametrial and para-aortic involvement in these cases, the operation was aborted and radiation therapy given. The remaining 17 patients underwent radical hysterectomy and pelvic lymphadenectomy 10-15 days following ChT. Five of these patients (29.4%) had pelvic node metastases. Three patients had positive margins. These 8 patients received postoperative radiotherapy. Twenty-four months later 15 patients were alive (87%) and 2 had died.
Full-Text [PDF 231 kb]   (1486 Downloads)    
Type of Study: Original Research | Subject: Gynecology & Obstetrics
Add your comments about this article : Your username or Email:
CAPTCHA
Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.